Posted On: 02/20/2015 12:00:40 PM
Post# of 30035
Dr. Urano's Progression With MANF in 2014:
I have copied two blog posts from Dr. Urano, the first from June 8, 2014 when he was still focused on "recombinant MANF injections." The second is from Sept. 28, 2014 when he states that he prefers "small molecules" to target endogenous MANF production within the body rather than recombinant MANF injections, which is what our MANF patent deals with. Other than using recombinant MANF injections to repair damage to the eye caused by wolframs/diabetes, Urano is not currently focused on using recombinant MANF as a cure for wolframs/diabetes. Many on this board think that whenever the word "MANF" is used, it is talking about our patent. It isn't. Read the following two blog posts and you'll see the progression Urano made from recombinant to small molecules.
June 8, 2014 blog:
"Yesterday, I articulated our strategy for protecting remaining beta cells and brain cells with MANF.
1. Inject recombinant MANF to patients.
2. Stabilize endogenous MANF< 3. Activate a receptor for MANF
I feel that these are realistic plans. The same strategy has been applied to GLP-1, a molecule produced in our guts, and GLP-1 related drugs are widely and successfully used for patients with type 2 diabetes."
We are currently focusing on “recombinant” MANF, and hope to expand our research in this area.
September 28, 2014 Post:
"How can we utilize MANF, a natural soluble factor produced in our body, to protect and proliferate remaining beta cells and neurons?
The key is to understand how MANF simulates the proliferation and enhances the function of remaining tissues. It seems like there are two independent mechanisms. There are two different mediators for MANF in our body. Thus, our goal is to develop two different types of small molecules to enhance the functions of endogenous MANF. Another option is to inject recombinant MANF. Because of several scientific reasons, we prefer small molecules at the moment."
I really don't understand why people here don't understand what Dr. Urano has plainly told us. I think there is a real scientific disconnect with shareholders here regarding MANF and wolframs/diabetes.
Now the Eye Franchise is another story!! Retinitis Pigmentosa, Glaucoma, Macular Degeneration, etc all can be treated with "recombinant MANF injections." That market is huge. We have plenty to be excited about without chanting false hopes about Urano and Saarma using recombinant MANF to cure diabetes!! That is not currently what they're focused on!!
I have copied two blog posts from Dr. Urano, the first from June 8, 2014 when he was still focused on "recombinant MANF injections." The second is from Sept. 28, 2014 when he states that he prefers "small molecules" to target endogenous MANF production within the body rather than recombinant MANF injections, which is what our MANF patent deals with. Other than using recombinant MANF injections to repair damage to the eye caused by wolframs/diabetes, Urano is not currently focused on using recombinant MANF as a cure for wolframs/diabetes. Many on this board think that whenever the word "MANF" is used, it is talking about our patent. It isn't. Read the following two blog posts and you'll see the progression Urano made from recombinant to small molecules.
June 8, 2014 blog:
"Yesterday, I articulated our strategy for protecting remaining beta cells and brain cells with MANF.
1. Inject recombinant MANF to patients.
2. Stabilize endogenous MANF< 3. Activate a receptor for MANF
I feel that these are realistic plans. The same strategy has been applied to GLP-1, a molecule produced in our guts, and GLP-1 related drugs are widely and successfully used for patients with type 2 diabetes."
We are currently focusing on “recombinant” MANF, and hope to expand our research in this area.
September 28, 2014 Post:
"How can we utilize MANF, a natural soluble factor produced in our body, to protect and proliferate remaining beta cells and neurons?
The key is to understand how MANF simulates the proliferation and enhances the function of remaining tissues. It seems like there are two independent mechanisms. There are two different mediators for MANF in our body. Thus, our goal is to develop two different types of small molecules to enhance the functions of endogenous MANF. Another option is to inject recombinant MANF. Because of several scientific reasons, we prefer small molecules at the moment."
I really don't understand why people here don't understand what Dr. Urano has plainly told us. I think there is a real scientific disconnect with shareholders here regarding MANF and wolframs/diabetes.
Now the Eye Franchise is another story!! Retinitis Pigmentosa, Glaucoma, Macular Degeneration, etc all can be treated with "recombinant MANF injections." That market is huge. We have plenty to be excited about without chanting false hopes about Urano and Saarma using recombinant MANF to cure diabetes!! That is not currently what they're focused on!!
(0)
(0)Scroll down for more posts ▼
